Original paper

**Precore/core mutations of hepatitis B virus genotype D arising in different states of infection**

Neda Sanaei*, Seyed Mohammad Ali Hashemi*, Seyyedeh Zahra Salehi Dehno, Mozhde Mahmoudi Asl, Maryam Moini, Seyed Ali Malek-Hosseini, Seyed Younes Hosseini, Jamal Sarvari

*Neda Sanaei and Seyed Mohammad Ali Hashemi contributed equally to this study.

Shiraz University of Medical Sciences, Iran

**Abstract**

**Aim of the study:** Precore/core variations and liver disease progression have been suggested. In this study, we aimed to determine the frequency of precore/core mutations in hepatitis B virus (HBV)-infected patients at various clinical stages.

**Material and methods:** In total, 73 HBV-infected patients including 26 inactive carriers (IC), 20 chronic active (CA), and 27 patients with liver cirrhosis/hepatocellular carcinoma (C/HCC) were randomly selected. The HBV DNA was extracted from the sera and subjected to nested PCR for amplification of precore/core region. The PCR product was then sequenced by the Sanger method.

**Results:** The stop codon of W28*(G1896A) was determined as the most prevalent mutation (55%) of the precore region. The comparison of groups also demonstrated that core substitutions at residues of S21, E40 and I105 (< 0.05) correlated with the development of the inactive carrier state. Furthermore, the total substitutions in Th epitopes (117-131) were significantly higher in the C/HCC group than the IC and CA groups (p = 0.001).

**Conclusions:** Our results indicated a high frequency of W28* mutation in HBV studied patients. Moreover, variations including S21, E40 and I105 and R151 that were mapped onto cellular epitopes might be related to inactive state development.

**Key words:** hepatitis B virus, precore, core, variation.

**Address for correspondence**

Dr. Jamal Sarvari and Dr. Seyed Younes Hosseini, Shiraz University of Medical Sciences, Iran, e-mail: sarvari@sums.ac.ir

---

**Introduction**

Nowadays, chronic hepatitis B infection remains a major cause of liver-related morbidity and mortality, even in the presence of an effective vaccine. It was predicted that 257 million people were living with chronic hepatitis B infection in 2015 [1]. A meta-analysis study in 2017 estimated that the prevalence rates of HBsAg and anti-HBcAb in Iran's general population were 1.79% (1.67% to 2.32%) and 13.59% (12.92% to 14.29%), respectively [2]. Moreover, the pooled prevalence of HBsAg among people who use drugs through injecting and otherwise was 4.8% and 2.9%, respectively [3]. Additionally, the pooled prevalence of HBsAg among Iranian hemodialysis patients was 4% [4].

The genome of HBV contains four overlapping open reading frames (ORFs) encoding the surface antigens (pre-s1, pre-s2 and s), precore (PC)/core (C) antigens, the polymerase, and a regulatory protein named X protein [5]. Based on the complete genome sequence, HBV strains are categorized into 10 genotypes, and it has been elucidated that some of them are more prone to mutations that contribute to the progression and severity of liver disease as well as poor antiviral responses, fibrosis, and hepatocellular carcinoma (HCC) progression [6]. Studies have shown that there is a relationship between variations in specific regions of the viral genome and progression to HBV-mediated liver diseases [6-8]. Previously, we described some mutations in the surface antigen sequence associated with the HBV infection outcome [9, 10].
The core or capsid protein (HBcAg) and HBeAg are encoded on the precore/core ORF. Some variations in this frame which result in the conversion of the expression level, protein structure, encapsidation properties, and antigenicity could be associated with disease/infection stage [11-13]. It has also been indicated that HBeAg-negative chronic patients respond much less than HBeAg-positive cases to conventional interferon therapy [14-16]. The HBeAg phenotype arises due to some substitutions and more particularly a stop codon W28* in the precore sequence which is associated with abrogation of expression in the HBeAg level [17, 18].

The studies on precore variations and the molecular mechanisms underlying the disease progression supported the role of HBeAg status in HCC development [5, 18].

In addition, some studies showed the importance of certain mutations in HBcAg, a protein with 183 residues length, in determining the clinical outcome [5]. HBcAg is an immunogenic protein, the most potent inducer of the immune response by cytotoxic T lymphocytes [19, 20]. Therefore, mutations in this region permit the virus to evade the host immune responses and establish a persistent infection [21-23]. Numerous HBcAg substitutions are associated with immune escape of the virus as well as more severe liver disease [5]. Moreover, Hayashi et al. showed that the core mutations such as T1938C (V13A) and A2051C (N51H) were correlated with HBV-related HCC and played a role in progression of liver disease in an Alaskan native population with HBV genotype F1b [24]. Additionally, they reported that A2051C increased the viral replication in vivo and in vitro [24]. In a study conducted in the Korean population, the five HBcAg mutations P5H/L/T, E83D, 1976/L, L100I, and Q182K/Stop were correlated with HBV-related HCC and played a role in progression of liver disease in an Alaskan native population with HBV genotype F1b [24]. In another study conducted in the Korean population, the five HBcAg mutations P5H/L/T, E83D, 1976/L, L100I, and Q182K/Stop were significantly more frequent in subjects with chronic hepatitis and cirrhosis [25]. Due to the host immune pressure in the course of viral persistence, accumulation of HBcAg mutations could occur and lead to the expansion of mutants that escape recognition by host immunity [5]. Determination of precore/core gene mutations in the immune epitopes at various clinical stages of HBV-infected patients would give additional insight into the role of these mutations in viral persistence and progression of liver damage. Therefore, in this study we aimed to determine the frequency of precore/core mutations in a small group of Iranian HBV-infected patients at various clinical stages and to clarify the association between precore/core mutations and disease progression.

**Material and methods**

**Patient selection**

In this cross-sectional study, 73 subjects including those with inactive carrier (IC) state, chronic active (CA) and cirrhosis/HCC (C/HCC) were enrolled consecutively from the Gastroenterohepatology Research Center, at Nemazee Hospital and Organ Transplantation Research Center at Central Abu-Ali Sina Hospital affiliated to Shiraz University of Medical Sciences during the years 2013 to 2017. All patients enrolled in the study were HBsAg positive; they were categorized into the three above-mentioned groups by a liver specialist according to biochemical, virological, and clinical records based on EASL guidelines [26]. The IC group included chronic patients with HBeAg negativity, a normal alanine aminotransferase (ALT)/aspartate aminotransferase (AST) level and < 2000 IU/ml viral load. The chronic active group consisted of chronic patients who were positive/negative for HBeAg, with an elevated level of ALT/AST and a viral load of > 2000 IU/ml up to 10^5 IU/ml. Cirrhosis and hepatocellular carcinoma patients were enrolled based on ultrasound scanning, histology grading, abnormal liver function tests, and a-fetoprotein levels. In prior studies we determined the HBV subgenotype of patients, and all patients were subgenotype D [9, 10].

Upon the patients’ agreement, 5 ml of venous blood without anti-coagulation was taken from them. The sera samples were isolated and kept at –20°C until the experiment time. The study was approved by the local ethics committee of Shiraz University of Medical Sciences (IR.SUMS.Rec.1396.S530).

**Viral DNA extraction and core gene amplification**

The HBV genome was extracted from the patients’ sera using the Cinnagen viral DNA extraction kit (Cin-
nagen Inc. Tehran, Iran), according to the manufacturer’s instructions. After extraction, a nested PCR was performed using outer and inner primers specific for the precore/core region. Primers were designed based on the genomic sequences of B, C and D genotypes of HBV (Table 1).

The first round of PCR reaction contained 0.5 pmol of the outer primer pair, 5 µl of the extracted DNA, 1.5 mM of MgCl₂, 1 U of Taq DNA polymerase (Cinnagen Inc, Tehran, Iran), and 200 mM of each dNTP. The final volume of the PCR reaction was 25 µl. The first round of nested PCR was as follows: denaturation at 95°C for 5 min, followed by 30 cycles of 95°C for 40 s, 54°C for 45 s, 72°C for 50 s, and a final extension cycle performed at 72°C for 3 min.

In the nested round, 2 µl of the first round PCR amplified products was then subjected to reaction containing each of the inner primers. The second round nested PCR was performed as the first round, except with 35 cycles and annealing temperature of 56°C. Negative and positive controls were also used to evaluate the test validity.

### Sequencing and multiple sequence alignment

PCR products were purified from the gel using PCR Product Purification Kit (MN Inc., Germany) and then sequenced by Sanger bidirectional sequencing using the internal primers. They were deposited in the NCBI (National Center for Biotechnology Information) data bank under accession numbers MG491124.1-MG491194.1. A group of precore/core reference/reliable sequences were obtained from the NCBI data bank regarding 7 main HBV genotypes and different genotype D sub-genotypes. The data resulting from sequencing were aligned with reference genomic sequence of HBV genotypes A-H using MEGA X software [Molecular Evolutionary Genetics Analysis across computing platforms (https://www.megasoftware.net/web_help_10/Citing_MEGA_In_Publications.htm)] to detect the putative amino acid substitutions. All differences between the patients’ sequences and reference genomic sequence of genotype D were considered as variations.

### Statistical analysis

For statistical analysis, SPSS software was employed. The χ² test was used for data analysis, and p < 0.05 was considered as significant. The results are presented as mean and standard deviation (SD).

### Results

#### Patients’ data

Out of 73 HBV patients, 27 were IC, 20 were CAH, and 26 were C/HCC. The mean age of the subjects in the IC, CA and C/HCC groups was 49.2 ±12.9, 40.7 ±14.2, and 50.9 ±11.8, respectively; the difference among the three groups was not significant (p = 0.72). Demographic characteristics and clinical data of the studied groups are shown in Table 2.

#### Variations of the precore sequence

Analysis and comparison among the retrieved sequences and reference ones revealed some types of substitutions in the precore region. The frequency distribution of mutations in hepatocellular carcinoma/cirrhosis, chronic active and inactive carrier groups was 26, 16 and 25, respectively. These

### Table 2. Demographic and clinical data of the study groups –

| Variable                | Cirrhotic/HCC | Chronic active | Inactive carrier | P-value |
|-------------------------|---------------|----------------|------------------|---------|
| No. of patients         | 26            | 20             | 27               | –       |
| Gender, n (%)           |               |                |                  |         |
| Male                    | 23 (88.5)     | 15 (75)        | 17 (63)          | 0.72    |
| Female                  | 3 (11.5)      | 5 (25)         | 10 (37)          |         |
| Mean age ±SD            | 50.9 ±11.8    | 40.7 ±14.2     | 49.2 ±12.9       | 0.094   |
| ALT ±SD                 | 48.8 ±27.7    | 40.3 ±24       | 21.5 ±9.6        | < 0.001 |
| AST ±SD                 | 76.0 ±50.2    | 34 ±12.3       | 21.9 ±4.7        | < 0.001 |
| HBeAg positive, n (%)   | 3/26 (11.5)   | 7/20 (35)      | 0/27 (0)         | < 0.01  |
| HBeAb, n (%)            | 23/26 (88.46) | 13/20 (65)     | 27/27 (100)      | 0.62    |
| HBeAg positive, n (%)   | 26/26 (100)   | 20/20 (100)    | 27/27 (100)      | –       |

ALT – alanine aminotransferase, AST – aspartate aminotransferase, SD – standard deviation
Table 3. Frequency of precore/core variations in the three studied groups

| Residue | Hepatocellular carcinoma/cirrhosis (n = 26) | Chronic active (n = 20) | Inactive carrier (n = 27) | P-value |
|---------|------------------------------------------|------------------------|--------------------------|---------|
| 27      | V/I(1)                                   |                         | V/I(1)                   | 0.68    |
| 28 (Precore) | W28* (13)                         | W28* (9)                | W28* (18)               | 0.693   |
| 29 (Precore) | G/D (12)                             | G/D (7)                 | G/D (6)                 | 0.19    |

Core mutations

| Residue | Hepatocellular carcinoma/cirrhosis (n = 26) | Chronic active (n = 20) | Inactive carrier (n = 27) | P-value |
|---------|------------------------------------------|------------------------|--------------------------|---------|
| 12      | T/S(6)                                   |                         | T/S(10)                  | 0.718   |
| 21      | S/P(1), S/T(2)                          | S/G(1)                  | S/T(5), S/A(8), S/H(1)   | 0.006   |
| 25      | P/T(9)                                   |                         | P/T(4)                   | 0.427   |
| 38      | Y/C/L                                    |                         | Y/F(2)                   | 0.682   |
| 40      | E/D(2)                                   |                         | E/D(9), E/Q(1)           | 0.04    |
| 45      | P/S(3)                                   |                         | P/S(5)                   | 0.46    |
| 49      | S/A(1)                                   |                         | S/T(6)                   | 0.11    |
| 59      | I/T(3), I/Y(1), I/N(1)                   | I/F(1)                  | I/T(2), I/V(1), I/C(1)   | 0.458   |
| 64      | E/D(7)                                   |                         | E/D(4)                   | 0.33    |
| 66      | M/I(2), M/L(3)                          | M/L(1), M/K(1), M/I(1) | M/I(2)                   | 0.757   |
| 67      | T/N(3), T/S(1)                          | T/N(4)                  | T/N(4), T/S(3)           | 0.742   |
| 69      | A/S(1), A/P(1)                          | A/G(2), A/S(2)          | A/S(2)                   | 0.413   |
| 77      | E/O(3), E/D(1)                          |                         | E/D(3), E/O(1)           | 0.571   |
| 79      | P/T(1), P/O(1)                          |                         | P/O(3)                   | 0.593   |
| 80      | I/T(8), I/T, I/V(5), I/A(3)              | I/T(8), I/V(3), I/A(3) | I/T(12), I/V(2), I/P(2), I/M(1), I/A(1) | 0.95 |
| 87      | S/(3)                                    | S/G(1)                  | S/G(3), S/H(1), S/R(1)   | 0.46    |
| 92      | N/I(3)                                   |                         | N/H(1), N/T(1)           | 0.9     |
| 93      | M/L(2), M/W(1)                          | M/L(1), M/W(1)          | M/V(1)                   | 0.597   |
| 105     | I/L(1)                                   |                         | I/L, I/V(4), I/T(2)      | 0.04    |
| 113     | E/D(4)                                   |                         | E/D(6), E/Q(2)           | 0.596   |
| 116     | I/L(5), I/V(4), I/K(1)                   |                         | I/V(2), I/L(2), I/V(2)   | 0.13    |
| 135     | P/O(3)                                   |                         | P/O(1), P/T(1)           | 0.75    |
| 147     | T/A(3), T/H(1), T/C(1)                   | T/C(1), T/A(1), T/S(1)  | T/A(2), T/C(1)           | 0.777   |
| 149     | V/I(4)                                   |                         | V/I(6)                   | 0.388   |
| 151     | –                                        | R/Q(1), R/S(1), R/P(1)  | R/Q(6), R/G(1)           | 0.05    |
| 153     | G/C(3)                                   | G/C(1)                  | G/S(1)                   | 0.543   |
| 155     | S/T(4)                                   | S/F(1), S/A(1), S/T(1)  | S/T(7)                   | 0.658   |
| 174     | –                                        | R/K(3)                  | R/K(2), R/T(1), R/I(2)   | 0.116   |
| 181     | S/P(2), S/R(1)                          | S/P(1)                  | S/P(2)                   | 0.75    |
| 182     | Q/K(2), Q/*                              | Q/H(1)                  | Q/H(3)                   | 0.752   |

Overall variations of core sequence among groups

Overall, the count of substitutions within the immune epitopes in the IC, CA and C/HCC groups was 200, 108, and 170 events, which was higher in IC subjects than CA and C/HCC ones (p > 0.05). The variations in these positions account for the virus immune

mutations appeared more commonly in 27, 28 and 29 residues, as listed in Table 3. The stop codon of W28* was detected in 55% (40/73) of the patients, which was the most frequent change in the precore sequence, but the difference among the groups was not significant (p = 0.69). The G29D substitution detected in 32% (25/73) of the subjects was the second one, but its frequency among the studied groups was also not significant (p = 0.19).
evasion. Additionally, some residues including S21 (24.6%), P25 (24.6%), E40 (24.6%), E64 (26%), T67 (20%), 80I (67.12%), E113 (21.9%), I116 (21.9%), V149 (27.3%), and S155 (19.1%) were determined as more variable positions alongside the core sequence of all patients (Table 3), and substitutions at S21 ($p = 0.006$), E40 ($p = 0.04$) and I1105 ($p = 0.04$) were significantly higher in the IC subjects. No deletion/insertion event was found in the sequences when compared with reference ones, but rare stop codon mutations such as L101* and L76* were also detected.

**Mutations in the cytotoxic T lymphocyte and T helper lymphocyte response regions**

Several variations in immune recognition sites along the HBcAg protein were detected. The CTL epitopes that had been considered in this study included 18-27, 88-96, 130-140, and 140-151, whereas Th-epitopes were 1-20, 50-69, 81-105, 117-131, and 141-165. The core sequences analysis showed that 156, 86 and 122 substitutions occurred in the IC, CA, and C/HCC groups, respectively. The total number of CTL epitope mutations was 54, 29 and 40 in the IC, CA, and C/HCC groups, respectively. The rate of variation at CTL-related residue 151 was higher in the IC than the CA and C/HCC groups. The most dominant variations were seen in CTL epitopes located at site 130-151; however, all variations in epitopes were higher in the IC group than CA, but they were not statistically significant (Table 4).

In the case of T-helper epitopes, variation in positions E64, T67, I105, and S155 was more common among all the groups; however, only I105 was significantly different among them ($p = 0.04$). The substitution rates of epitopes including sites 50-69 and 141-165 were more frequent than other Th epitopes in all groups. In sum, the total substitutions in Th epitopes (117-131) were significantly higher in the C/HCC group than the IC and CA groups ($p < 0.001$).

**Table 4.** Number of amino acid substitutions alongside the entire core sequences

| Hepatocellular carcinoma/cirrhosis (n = 26) | Chronic active (n = 20) | Inactive carrier (n = 27) | Cell subsets | Epitope sequence | P-value |
|--------------------------------------------|------------------------|--------------------------|--------------|------------------|---------|
| S21T(2)/P, F24Y(2), P25T(9), V27L          | S21G/T, P25T(5)        | S21T(4)/A8/H, F24Y, P25T(4), S26A, V27I | CTL cell     | 18-27            | 0.25    |
| N92H(3), M93L(2)/W                         | N92H/T, M93L(2)/L, G94A| T91S/E, N92H(3)/T, M93V | CTL cell     | 88-96            | 0.921   |
| P130L/Q, A131P, Y132T(2), R133G, P135Q(3), I139L, L143P, T146S, T147A(3)/C, V149(4) | P130L, A131G, P135Q, L143P, T147A/C, V149(6), R151S/Q/P | A131P, P135T/Q, L140*, T142M, L143P, T147A/C, V149(10), R151N(6)/G | CTL cell     | 130-151           | 0.679  |
| T125(6), V13L, E14Q/D                      | T125(6), E14Q          | D2N, T125(10), E14Q(3), L16(6) | Th1 cell     | 1-20             | 0.297   |
| P50A, A54V, R56G, I59Y(3)/V, C61R, W62C, G63W, E64D(7), M66L, T67N(3)/S, A69S/P | L55I(2), I59E, C61W, W62G, E64D(7)/N, M66L/K, T67N(4), L68P, A69G(2)/Q(2) | P50A(3), L55I, G57L/R, I59T(2)/V/C, C61R, G63A(2), E64D(4), M66L(2), Y67S(3)/N(4), L68P, A69S(2) | Th1 cell     | 50-69             | 0.857   |
| L84Q, S87T(3), N92H(3)                     | L84G, N92H/T, M93L, G94A | L84P/Q, S87G(3)/H/R, T91S/E | Th1 cell     | 81-105            | 0.25    |
| M93L(2)/W, F97V, R98Q, L100R, W102G, H104Y, I105L | P130I, A131G, P135Q, L143P, T147A/C, V149(6), R151S/Q/P | A131P, P135T/Q, L140*, T142M, L143P, T147A/C, V149(10), R151N(6)/G | CTL cell     | 18-27            | 0.25    |
| E117G, Y118E, L119W, V120A, F122S, V124G, W125G(2), R127A/G, T128L, P129L, P130Q, A131P | L143P, T147S/C/A, V149(6), I151P/S/Q, G153C, S155T/T/A | T142M, L143P, T146S, T147A(2)/C, V149(10), R151Q(6)/G, G153S, S155T(7), P156T(2) | Th1 cell     | 141-165           | 0.329   |
| L143P, T147S(3)/N/C, V149(4), G153C(3), S155T(4), R157E, R165K | L143P, T147S/C/A, V149(6), I151P/S/Q, G153C, S155T/T/A | T142M, L143P, T146S, T147A(2)/C, V149(10), R151Q(6)/G, G153S, S155T(7), P156T(2) | Th1 cell     | 141-165           | 0.329   |
| W71G, V72W, G73V, L76V, E77D(3)/Q, D78A, P79Q/T, I80T(9)/V(5)/A(3), L84Q, S87T(3) | W71R, G74V, E77D(3)/Q, I80T(8)/V(3)/A(3), S87G, W71R, G74S(3)/A/V, L76*, E77D(3)/Q, P79Q(5), I80T(12)/V(2)/A(1)/P(2)/M, L811, L84P/Q, S87G(2)/H/R | W71R, G74S(3)/A/V, L76*, E77D(3)/Q, P79Q(5), I80T(12)/V(2)/A(1)/P(2)/M, L811, L84P/Q, S87G(2)/H/R | B cell       | 71-89             | 0.512   |
| R127A/G, T128L, P129L, P130Q, A131P, Y132T, R133G, P135Q(3) | P130I, A131G, P135Q, A131P, Y132T, R133G, P135Q(3) | A131P, P135Q/T | B cell       | 126-135           | 0.94    |
Mutations in the B lymphocyte epitope region

Sequence analysis of HBcAg indicated 108 mutations in the target epitopes for B-cells, as shown in Table 4. Among them, the most variable residues were located on epitope 71-89. The total frequency of B-cell epitope variations was determined to be 42, 24 and 42 for the IC, CA and C/HCC groups, respectively.

Discussion

Although the HBV vaccine was introduced more than 35 years ago, chronic HBV infection is one of the most important health problems worldwide today. Iran implemented general HBV vaccination in 1993 and is now classified as a low prevalence country with around 1,347,000 chronic HBV infections [2, 27].

The precore/core variations would possibly determine the fate of HBV infection as they modify encapsidation, HBcAg production, immune response, inflammation, ER, and DNA damage [18]. Some studies have reported that HBV infected patients with the presence of precore/core mutations significantly more often developed severe liver disease and HCC [18, 28].

The result of our study showed that a precore point mutation, G1896A, that converts the tryptophan to a stop codon (W28*), was the most common variation in the patients, as detected in chronic HBV in Asia and the Mediterranean region [18]. This mutation disrupted HBcAg production and was suggested to be involved in disease progression toward HCC [29]. The frequency of this mutation was higher in the C/HCC group than the IC and CA groups, but it was not statistically significant. In the same line, in another study in Shiraz, Iran, Taghavi et al. reported that 31.8% (14/44) of patients had mutations in the precore region (G1896A) [30]. Moreover, Kim et al. reported no significant correlation between W28* and higher susceptibility to HCC [25]. In addition, it has been recently reported that chimeric mice expressing a recombinant virus containing the PCG1896A or basal core promoter (BCP)/IC/2051 mutations demonstrated higher levels of virus replication and viral protein expression than mice expressing the wild-type strain [24]. Also, microarray analysis of the liver transcriptome of these mice showed increased expression of the genes involved in cell proliferation and hepatocarcinogenesis in comparison with the control group [24].

Our results also showed G29D precore mutation at the highest frequency in the C/HCC group among the groups, but the difference was not statistically significant. In this regard, a meta-analysis study showed a significant correlation between G29D mutation and higher risk of HCC [31].

On the core protein, the types of substitutions including inside and outside of epitopes were suggested to be important. This investigation indicated that numerous substitutions in the immune epitopes were coincidently associated with more severe liver disease. The substitution E180A which was not mapped in an epitope region was suggested to be significantly associated with disease progression by other strategies [32]. There were some variations such as E77Q, E113Q, S181P/H and Q182K/*Stop outside of the epitope regions which have previously been reported to accumulate with disease progression [33-35]. However, in spite of their prevalence, our data showed that E80Q/D, E113D/Q, S181P/R and Q182K/*Stop variations were not statistically significantly different among the groups. Instead, as a new finding, the prevalence of E40D/Q was significantly higher in the IC subjects than CA and C/HCC groups. Further mechanisms accounting for these mutations in infection progression require additional molecular and virologic investigations.

The core substitutions of epitopes which are associated with severe liver disease have been reported by others. Jia et al. investigated the association between HBc mutations and the post-operative prognosis of HBV-related HCC, which demonstrated that the HBc E77 mutation was more associated with shorter overall survival than other mutations [5]. Al-Qahtani et al. reported 6 core mutations (F24Y, E64D, E77Q, A80I/T/V, L116I, and E180A) related to the progression of the disease to cirrhosis and HCC [32]. They also found that F24Y, E64D, and V91S/T mutations were located in the T-cell epitope regions, and E77Q, A80I/T/V, and L116I were located within the B-cell epitope regions [32]. The comparison of core sequence among our groups indicated that substitutions at residues S21, E40 and I105 were possibly accelerating the development of the IC state. This was also supported by amino acid changes at the CTL epitopes including S21, P25 and V149 that were significantly more frequent in the IC group. In line with this, Ghabeshi et al. reported that some mutations of HBc gene sequence in the T helper, CTL and B cell epitopes in asymptomatic HBV infected blood donors can cause a decrease in Hbc and HBc antigenicity and an increase in escape mutants [36]. In addition, the rate of mutation at position 21 (S/T, S/A and S/H) in the CTL epitope in IC subjects was significantly higher than the CA and C/HCC groups. In theory, mutations in the core immune epitopes would subvert the immune responses to permit persistent HBV infection. It was also reported
that a distribution pattern of core mutations detected in the immune and non-immune regions was associated with progression of the disease [18].

The present study also demonstrated that the rates of F24Y, E64D, E77Q, L116I, and E180A mutations were higher in the C/HCC patients than the other groups; however, these differences were not statistically significant. Recently, Zhang et al. found that HBc L60V variation was associated with higher viral loads, necroinflammation of the liver, and probably a poor prognosis [37]. They proposed that this variation could influence both virus replication and T cell responses [37]. Mohamadkhani et al. suggested that the frequency of HBc mutations in the CTL epitope regions and C-terminal domain was associated with a higher stage of fibrosis [38]. Likewise, similar studies indicated that mutations of CTL epitopes at the C-terminal of the core might enhance the development of fibrosis [38]. In sum, there are several mutations considered as effective variations to enhance the progression of the liver disease. Accumulation of these mutations during viral persistence could be the result of escape recognition of the infected cell by the immune system and progression of liver impairment. Therefore, more efforts should be made to understand the effect of these mutations on the liver disease progression during HBV infection.

Some studies have shown that the locations of effective mutations are definitely mapped more on specific regions such as the 80-120 sequence [25, 39-41]. In our study, there was not a similar pattern over different parts of the core. Instead, it was found that the rate of substitutions in the IC group was higher than in the other groups.

Our study had some limitations such as a small sample size as well as a lack of available data regarding the viral replication parameters. However, these results help us to know the frequency of precore/core mutations in HBV infected patients in Fars province and greatly improve our understanding of precore/core mutations, mostly within the immune epitopes.

Conclusions

In conclusion, it suggested that variations including S21, E40, I105 and R151 which are located on cellular epitopes are associated with the immune inactive state in HBV-infected patients. Furthermore, more than half of the HBV-infected subjects harbored the stop codon W28* of the precore region that is responsible for the HBeAg negative state. However, a more detailed study on a larger population of HBV-infected patients is recommended to confirm this claim.

Acknowledgments

The present study was extracted from the thesis written by Seyedeh Zahra Salehi Dehno (grant no: 95-12797) and Mozhde Mahmoudi Asl (grant no: 96-14812).

Funding source

The present study was financially supported by Shiraz University of Medical Sciences (grant no: 95-12797 and 96-14812).

Disclosure

The authors declare no conflict of interest.

References

1. WHO. Hepatitis B. https://www.who.int/news-room/fact-sheets/detail/hepatitis-b.
2. Hajarizadeh B, Mesgarpour B, Nasiri MJ, et al. Estimating the prevalence of hepatitis B virus infection and exposure among general population in Iran. Hepat Mon 2017; 17: 11.
3. Rostam-Abadi Y, Rafieanmeh H, Gholami J, et al. Hepatitis B virus infection among people who use drugs in Iran: a systematic review, meta-analysis, and trend analysis. Harm Reduct J 2020; 17: 1-19.
4. Djalalinia S, Ghorbani NR, Tajbaksh R, et al. Hepatitis B virus infection in Iranian hemodialysis patients. Iran J Kidney Dis 2018; 12: 1-9.
5. Jia J, Li H, Wang H, et al. Hepatitis B virus core antigen mutations predict post-operative prognosis of patients with primary hepatocellular carcinoma. J Gen Virol 2017; 98: 1399-1409.
6. Paudel D, Suvedi S. Hepatitis B genotyping and clinical implication. Hepatitis B and C. IntechOpen 2019.
7. Sugiyama M, Tanaka Y, Kurbano F, et al. Direct cytopathic effects of particular hepatitis B virus genotypes in severe combined immunodeficiency transgenic with urokinase-type plasminogen activator mouse with human hepatocytes. Gastroenterology 2009; 136: 652-662.e3.
8. Sugiyama M, Tanaka Y, Kato T, et al. Influence of hepatitis B virus genotypes on the intra-and extracellular expression of viral DNA and antigens. Hepatology 2006; 44: 915-924.
9. Hosseini SY, Sanaei N, Fattahi MR, et al. Association of HBsAg mutation patterns with hepatitis B infection outcome: asymptomatic carriers versus HCC/cirrhotic patients. Ann Hepatol 2019; 18: 640-645.
10. Taghiabadi M, Hosseini SY, Gorzin AA, et al. Comparison of pre-S1/S2 variations of hepatitis B virus between asymptomatic carriers and cirrhotic/hepatocellular carcinoma-affected individuals. Clin Exp Pathol 2019; 5: 161-168.
11. Ito K, Kim KH, Lok ASF, Tong S. Characterization of genotype-specific carboxyl-terminal cleavage sites of hepatitis B virus e antigen precursor and identification of furin as the candidate enzyme. J Virol 2009; 83: 3507-3517.
12. Baumeister MA, Medina-Selby A, Coit D, et al. Hepatitis B virus e antigen specific epitopes and limitations of commercial anti-HBe immunoassays. J Med Virol 2000; 60: 256-263.
13. Laine S, Thouard A, Derancourt J, et al. In vitro and in vivo interactions between the hepatitis B virus protein P22 and the cellular protein gC1qR. J Virol 2003; 77: 12875-12880.

14. Saikia N, Talukdar R, Mazumder S, et al. Management of patients with HBeAg-negative chronic hepatitis B. Postgrad Med J 2007; 83: 32-39.

15. Hui CK, Lau GK. Treatment of hepatitis B e antigen-negative patients. Curr Treat Options Gastroenterol 2007; 10: 474-482.

16. Yeh ML, Peng CY, Dai CY, et al. Pegylated-interferon alpha therapy for treatment-experienced chronic hepatitis B patients. PLoS One 2015; 10: e0122259.

17. Tong S, Kim KH, Chante C, et al. Hepatitis B virus e antigen variants. Int J Med Sci 2005; 2: 2.

18. Kim H, Lee SA, Do SY, Kim BJ. Precore/core region mutations of hepatitis B virus related to clinical severity. World J Gastroenterol 2016; 22: 4287-4296.

19. Shannugam S, Velu V, Nandakumar S, et al. Low frequency of precore mutants in anti-hepatitis B e antigen positive subjects with chronic hepatitis B virus infection in Chennai, Southern India. J Microbiol Biotechnol 2018; 18: 1722-1728.

20. Kim H, Jee Y, Mun H, et al. Comparison of full genome sequences between two hepatitis B virus strains with or without preC mutation (A1896) from a single Korean hepatocellular carcinoma patient. World J Microbiol Biotechnol 2007; 17: 701.

21. Kim D, Lyoo KS, Smith D, et al. Number of mutations within CTL-defined epitopes of the hepatitis B Virus (HBV) core region is associated with HBV disease progression. J Med Virol 2011; 83: 2082-2087.

22. Bock CT, Buerke B, Tillmann HL, et al. Relevance of hepatitis B core gene deletions in patients after kidney transplantation. Gastroenterology 2003; 124: 1809-1820.

23. Preikschat P, Günther S, Reinhold S, et al. Complex HBV populations with mutations in core promoter, C gene, and pre-S region are associated with development of cirrhosis in long-term renal transplant recipients. Hepatology 2002; 35: 466-477.

24. Hayashi S, Khan A, Simons BC, et al. An association between core mutations in hepatitis B virus genotype F1b and hepato-cellular carcinoma in Alaskan native people. Hepatology 2019; 69: 19-33.

25. Kim DW, Lee SA, Hwang ES, et al. Naturally occurring precore/core region mutations of hepatitis B virus genotype C related to hepatocellular carcinoma. PLoS One 2012; 7: e47372.

26. Liver EAFTSOT. EASL clinical practice guidelines: management of chronic hepatitis B virus infection. J Hepatol 2012; 57: 167-185.

27. Dowran R, Malekzadeh M, Nourrellahi T, et al. The prevalence of hepatitis B virus markers among students of Shiraz University of Medical Sciences. Adv Biomed Res 2021; 10: 7.

28. Alexopoulou A. Mutants in the precore, core promoter, and core regions of hepatitis B virus, and their clinical relevance. Ann Gastroenterol 2009; 13-23.

29. Laskus T, Persing DH, Nowicki MJ, et al. Nucleotide sequence analysis of the precore region in patients with fulminant hepatitis B in the United States. Gastroenterology 1993; 105: 1173-1178.

30. Taghavi SA, Tabibi M, Eshraghian A, et al. Prevalence and clinical significance of hepatitis B Basal core promoter and precore gene mutations in southern Iranian patients. Hepat Mon 2010; 10: 294-297.

31. Liao Y, Hu X, Chen J, et al. Precore mutation of hepatitis B virus may contribute to hepatocellular carcinoma risk: evidence from an updated meta-analysis. PLoS One 2012; 7: e38394.